COVID-19: A Personalized Cardiometabolic Approach for Reducing Complications and Costs. The Role of Aging beyond

J Saban-Ruiz1, D Ly-Pen

  • 1Prof. Saban-Ruiz, MD, PhD, d-médical Clinic, Madrid, Spain, psaban@gmail.com.

Insights

COVID-19 involves more than infection; cardiovascular and metabolic factors significantly impact outcomes. This review integrates these aspects, considering aging and immunosenescence for better management of high-risk patients.

Area of Science:

  • Cardiovascular Medicine
  • Metabolic Health
  • Immunology
  • Gerontology

Background:

  • COVID-19 presents complex challenges beyond SARS-CoV-2 infection, involving disproportionate immune responses.
  • Key risk factors include older age, diabetes, and pre-existing cardiovascular diseases like hypertension, heart failure, and coronary artery disease.
  • Hospitalizations are frequently complicated by hyperglycemia and heart failure, with other cardiovascular events like stroke being less common.

Purpose of the Study:

  • To provide the first integrated review of cardiovascular and metabolic aspects of COVID-19, aligning with Cardiometabolic Health/Medicine guidelines.
  • To analyze personalized treatment strategies, including ACE inhibitors (ACEIs), ARBs, statins, and heart failure management in diabetic patients.
  • To explore aging as a dynamic process and immunosenescence, aiming to improve resilience against infectious diseases.

Main Methods:

  • Literature review focusing on cardiovascular and metabolic comorbidities in COVID-19.
  • Analysis of personalized medicine approaches for managing high-risk patients.
  • Investigation of molecular mechanisms of aging and immunosenescence, including endoplasmic reticulum stress and autophagy.

Main Results:

  • Older age, diabetes, and cardiovascular disease are critical risk factors for severe COVID-19 outcomes.
  • Hyperglycemia and heart failure are common during hospitalization, impacting patient prognosis.
  • Aging and immunosenescence, linked to endoplasmic reticulum stress and autophagy, play a role in disease severity and resilience.

Conclusions:

  • An integrated, personalized approach to cardiometabolic health is crucial for managing COVID-19 in high-risk populations.
  • Understanding aging and immunosenescence can lead to strategies for healthier elders resistant to infections.
  • This review offers insights for physicians to reduce hospital stay, complications, and costs associated with COVID-19.

Related Concept Videos

Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
214
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
773
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
259
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
522
Cardiomyopathy VI: Nursing Management01:29

Cardiomyopathy VI: Nursing Management

Assessment: Nursing management of patients with cardiomyopathy begins with a thorough assessment of the patient's history, including a family history of cardiomyopathy or sudden cardiac death, personal history of heart disease, hypertension, diabetes, and any alcohol consumption or drug use.During the physical examination, assess vital signs, look for signs of heart failure (such as edema, jugular venous distention, and cyanosis), auscultate for abnormal heart sounds (like murmurs and gallops),...
218
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
263